DDInter364 DDInter1660
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, deb
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. The tablet formulation was approved for oral administration in September 2019. Semaglutide works by binding to and activating the GLP-1 receptor, thereby stimulating insulin secretion and reducing blood glucose. The subcutaneous injection is administered once weekly and the tablet is administered once a day. Semaglutide offers a competitive advantage over other drugs used to manage diabetes, which may require several daily doses. Clinical trials have determined that this drug reduces glycosylated hemoglobin (HbA1c) levels and reduces body weight, proving to be effective for patients with type 2 diabetes. In June 2021, semaglutide was approved by the FDA for chronic weight management in adults with general obesity or overweight who have at least one weight-related condition, marking semaglutide as the first approved drug for such use since 2014. The use of semaglutide in weight management is also approved by Health Canada and the EMA. On May 31, 2023, the FDA issued a warning regarding the use of compounded semaglutide after receiving adverse event reports. The use of salt forms of semaglutide, including semaglutide sodium and semaglutide acetate, has not been proven to be safe or effective.
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Chlorpropamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Semaglutide
Chlorpropamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Semaglutide
Chlorpropamide {u} (Compound) resembles {v} (Compound) Sulfacetamide
Sulfacetamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Semaglutide
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pasireotide
Pasireotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Chlorpropamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pasireotide
Pasireotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Chlorpropamide {u} (Compound) resembles {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lithium carbonate
Lithium carbonate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Chlorpropamide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Chlorpropamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Chlorpropamide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Semaglutide
Chlorpropamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Semaglutide
Chlorpropamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Chlorpropamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Semaglutide
Chlorpropamide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Chlorpropamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Chlorpropamide (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Chlorpropamide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide